Physician profile
Laura Helm
NPI 1104003656
$3,636.72
in general payments reported to CMS, 2019-2025
33 companies · $63.40 in 2025
The $63.40 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,921 · 2022: $836 · 2023: $617 · 2024: $200 · 2025: $63.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $980.50 | 2021 | |
| Abbvie INC. | $853.35 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $222.35 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.30 | 2021-2023 | |
| Lilly USA, LLC | $175.85 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $115.44 | 2022-2023 | |
| Collegium Pharmaceutical, INC. | $111.13 | 2021-2025 | Belbuca |
| Takeda Pharmaceuticals U.S.A., INC. | $99.76 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $98.29 | 2022-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Novo Nordisk INC | $97.51 | 2021-2022 | |
| Lucid Diagnostics INC. | $95.46 | 2022-2023 | |
| Amgen INC. | $86.11 | 2021-2022 | |
| Glaxosmithkline, LLC. | $60.02 | 2021-2025 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $49.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $38.58 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $34.94 | 2021-2022 | |
| Gilead Sciences, INC. | $34.65 | 2021-2022 | |
| Pfizer INC. | $29.89 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $27.22 | 2023 | Quviviq |
| Eisai INC. | $24.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.73 | 2022 | |
| Abbott Laboratories | $21.04 | 2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $19.29 | 2024 | Veozah |
| Sanofi Pasteur INC. | $18.94 | 2021 | |
| Nevro Corp. | $18.31 | 2022 | |
| Cranial Technologies, INC | $17.95 | 2023 | Doc Band |
| Acella Pharmaceuticals, LLC | $15.86 | 2025 | NP Thyroid 60 |
| Collaborative Care Diagnostics, LLC | $14.58 | 2023 | |
| Currax Pharmaceuticals LLC | $13.09 | 2023 | Nexletol, Onzetra Xsail, Contrave |
| Galderma Laboratories, L.P. | $12.76 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.68 | 2022 | |
| Qorumpartners | $12.60 | 2022 | |
| Upsher-Smith Laboratories LLC | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Helm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.